Tirzepatide is not recommended in pregnancy. It may also reduce the effectiveness of oral contraceptives because it delays gastric emptying — the label advises switching to a non-oral method or adding a barrier method for four weeks after starting and after each dose increase.
Contraception interaction
Delayed gastric emptying can reduce absorption of oral contraceptives. Eli Lilly's labeling advises patients using oral hormonal contraception to switch to a non-oral method, or to add a barrier method, for four weeks after starting tirzepatide and for four weeks after each dose escalation.
This is one of the most under-communicated facts in telehealth GLP-1 care. If nobody mentioned it to you, that tells you something about the quality of the clinical review you received.
Planning a pregnancy
Discuss timing with your clinician. Because tirzepatide has a long half-life, a washout period before conception is typically advised. Weight loss itself can restore ovulation in people with PCOS, so unintended pregnancy is a genuine consideration for people who assumed they could not conceive.
If you become pregnant while taking it
Contact your clinician promptly. Do not simply continue. There is a manufacturer pregnancy exposure registry your clinician can discuss with you.
Common questions
How long does it take to see results on tirzepatide?
Appetite change usually arrives within the first one to two weeks, often before the scale moves. Meaningful weight loss typically becomes visible between weeks 4 and 12, with the steepest part of the curve between months 3 and 9. Trial weight loss continued accumulating through week 72.
Does insurance cover tirzepatide?
It depends on your plan and your diagnosis. Many commercial plans exclude weight-management drugs entirely. Zepbound carries a specific FDA indication for moderate-to-severe obstructive sleep apnea with obesity, and plans that exclude weight loss often cover a diagnosed sleep disorder. With type 2 diabetes, Mounjaro is on-label.
What are the most common tirzepatide side effects?
Nausea (roughly 24–33%), diarrhea (19–23%), constipation (16–17%) and vomiting (8–12%). They cluster in the days after each dose increase and usually settle within one to two weeks at each new dose. Constipation is the one that most often persists.
Do I need a prescription for tirzepatide?
Yes, always — for brand and compounded alike. Any seller shipping tirzepatide without a prescription from a licensed prescriber is operating illegally, and the product should not be considered pharmaceutical grade.
People also ask about tirzepatide pregnancy
What is tirzepatide pregnancy?
Tirzepatide pregnancy is covered in full on this page, with the clinical detail drawn from the tirzepatide prescribing information and the published SURMOUNT and SURPASS trial program, and any price figures drawn from our tracked dataset and dated to their last verification.
Does tirzepatide pregnancy apply to compounded tirzepatide as well as Zepbound?
The molecule is the same, so the clinical content applies to both. What differs is regulatory status, dose metering and price: compounded preparations are not FDA-approved, arrive as a multi-dose vial you measure yourself, and cost a fraction of the brand routes.
How much does tirzepatide pregnancy cost per month in 2026?
Compounded tirzepatide runs from $133 per month at the entry dose across the 21 compounded programs we track. At a 10 mg maintenance dose the cheapest tracked route is Oak Longevity at $199 per month, or about $2,388 for a first year on the standard escalation. Brand Zepbound through manufacturer self-pay sits well above that and pharmacy retail well above again. Verified 2026-08-05.
Is tirzepatide pregnancy FDA-approved?
Brand tirzepatide (Zepbound and Mounjaro) is FDA-approved. Compounded tirzepatide is not: FDA does not approve compounded drugs and does not review them for safety, effectiveness or quality before they are marketed. The active molecule is the same; the regulatory review is not.
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.